Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04507438 · ClinicalTrials.gov registry record · Phase 2
The Effect of Donepezil on Glycemic Control in Type II Diabetics
A Phase 2 study, sponsored by University of Maryland, Baltimore.
- Terminated
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT04507438 is a Phase 2 study that was terminated before completion, run by University of Maryland, Baltimore. The registered enrollment target is 7 participants.
The verdict
NCT04507438, a Phase 2 study, was terminated before completion, sponsored by University of Maryland, Baltimore.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
The purpose of the study is to establish the effectiveness of the drug Donepezil in treating Type 2 Diabetes Mellitus compared to a control treatment. Donepezil is not approved by the FDA to treat Type 2 Diabetes Mellitus and its use in this research is experimental. 50 patients with Type 2 Diabetes Mellitus (Adult Onset Diabetes Mellitus) will be randomized to either the donepezil treatment group or the control group after screening. (25 patients in each arm; a total of 50 patients). Both men and women shall be enrolled.Donepezil shall be orally administered to the study group. Control group will get an orally administered placebo which is an inert compound, lactose. Wk0 will be the randomization visit. The patients will take the drug for 8 weeks and the last follow up visit will be the last day of week 8.
Interventions
- DRUG Placebo Oral Tablet
- DRUG Donepezil 5-10 Mg Oral Tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2019-07-12 |
| Est. Completion | 2023-09-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04507438
The ClinicalTrials.gov registry entry for NCT04507438 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo Oral Tablet is the first listed.
NCT04507438 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04507438 about?
NCT04507438 is a clinical study titled "The Effect of Donepezil on Glycemic Control in Type II Diabetics". The purpose of the study is to establish the effectiveness of the drug Donepezil in treating Type 2 Diabetes Mellitus compared to a control treatment. Donepezil is not approved by the FDA to treat Type 2 Diabetes Mellitus and its use in this research is experimental. 50 patients with Type 2 Diabetes...
What is the current status of trial NCT04507438?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2019-07-12. Estimated completion is 2023-09-12.
What interventions are being tested in trial NCT04507438?
The interventions under investigation include: Placebo Oral Tablet (DRUG), Donepezil 5-10 Mg Oral Tablet (DRUG).
Who is sponsoring clinical trial NCT04507438?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.